Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 8.01 (Other Events). KRRO-111 added to Korro Bio’s development pipeline for potential Alpha-1 Antitrypsin Deficiency treatment.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- KRRO-111 added to Korro Bio’s development pipeline for potential Alpha-1 Antitrypsin Deficiency treatment
- New pipeline program broadens Korro’s clinical development portfolio and future value drivers
- Press release and updated investor presentation provide additional program details and corporate strategy context
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.